Start of Pivotal Phase III Trial for Lutathera® in Cancer Patients With Progressive Midgut Carcinoid
The study, known as NETTER-1, is a Phase III, international, multi-center, randomised, comparator-controlled, parallel-group study evaluating the efficacy and safety of Lutathera ® compared to ...
Radiopharmaceuticals, along with cell and gene therapy, is one of the advanced drug platforms Novartis has pegged for long-term growth. But that ambition has hit a small setback. Lutathera, the first ...
Lutathera plus Sandostatin improved progression-free survival in patients with advanced gastric neuroendocrine tumors, research showed. Patients with advanced gastric neuroendocrine tumors (NETs) who ...
Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic ...
NETTER-1 study, showing clinically meaningful and significant results for Lutathera (77Lu-DOTA0-Tyr3-Octreotate) in patients with metastatic midgut neuroendocrine tumors (NETs). The data will be ...
Basel, June 3, 2021 — Novartis today reported the final analysis from the NETTER-1 phase III study comparing treatment using Lutathera® (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 ...
SAINT-GENIS-POUILLY, France, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international specialist in Molecular Nuclear Medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results